Kos Seeks Court Order to Block Launch of Generic Niaspan

Law360, New York (March 9, 2005, 12:00 AM EST) -- Kos Pharmaceuticals has filed a lawsuit to block Barr Pharmaceuticals from launching generic versions of Kos' cholesterol-lowering drug Niaspan upon the expiration of a 30-month stay of approval by the U.S. Food and Drug Administration.

The lawsuit, filed in U.S. District Court for the Southern District of New York, seeks a temporary restraining order and a preliminary injunction to prevent Barr from launching generic versions of Niaspan 500 mg, 750 mg and 1000 mg extended-release tablets.

The FDA has tentatively approved Barr's applications for the three...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.